Entrada Therapeutics (NASDAQ:TRDA) CFO Kory James Wentworth Sells 5,089 Shares of Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Kory James Wentworth sold 5,089 shares of the company’s stock in a transaction on Monday, March 9th. The stock was sold at an average price of $13.00, for a total transaction of $66,157.00. Following the completion of the transaction, the chief financial officer directly owned 132,898 shares in the company, valued at $1,727,674. This trade represents a 3.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Kory James Wentworth also recently made the following trade(s):

• On Tuesday, March 10th, Kory James Wentworth sold 11,388 shares of Entrada Therapeutics stock. The shares were sold at an average price of $13.02, for a total value of $148,271.76.
• On Wednesday, March 4th, Kory James Wentworth sold 7,988 shares of Entrada Therapeutics stock. The stock was sold at an average price of $12.25, for a total transaction of $97,853.00.

Entrada Therapeutics Price Performance

NASDAQ:TRDA traded down $0.83 during midday trading on Thursday, reaching $12.68. The stock had a trading volume of 27,708 shares, compared to its average volume of 231,921. Entrada Therapeutics, Inc. has a 1-year low of $4.93 and a 1-year high of $13.65. The firm’s fifty day simple moving average is $11.23 and its 200-day simple moving average is $8.86. The stock has a market capitalization of $485.20 million, a P/E ratio of -3.65 and a beta of -0.12.

Entrada Therapeutics (NASDAQ:TRDA) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.94) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.38. The firm had revenue of $1.30 million during the quarter, compared to the consensus estimate of $7.41 million. Entrada Therapeutics had a negative net margin of 565.48% and a negative return on equity of 39.83%. On average, equities research analysts anticipate that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on TRDA shares. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Entrada Therapeutics in a research report on Wednesday, February 18th. Oppenheimer began coverage on Entrada Therapeutics in a report on Wednesday, January 28th. They issued an “outperform” rating and a $21.00 price target for the company. Wall Street Zen raised Entrada Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Guggenheim upgraded Entrada Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 11th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Entrada Therapeutics in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Entrada Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.50.

Institutional Trading of Entrada Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Royce & Associates LP lifted its stake in Entrada Therapeutics by 54.8% in the third quarter. Royce & Associates LP now owns 345,507 shares of the company’s stock valued at $2,004,000 after buying an additional 122,256 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Entrada Therapeutics in the second quarter valued at about $166,000. Los Angeles Capital Management LLC lifted its holdings in Entrada Therapeutics by 60.6% during the 2nd quarter. Los Angeles Capital Management LLC now owns 44,632 shares of the company’s stock worth $300,000 after purchasing an additional 16,840 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Entrada Therapeutics in the third quarter valued at approximately $325,000. Finally, AXQ Capital LP bought a new stake in Entrada Therapeutics during the third quarter worth $67,000. Institutional investors and hedge funds own 86.39% of the company’s stock.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.